Table 2. Histopathologic characteristics of FCCTX in CCFR compared with Lynch syndrome and non-Amsterdam Criteria-1 colorectal cases.
| Characteristic, n (%) | FCCTX (n=146) | Lynch (n=245) | Non-AC1 (n=7,878) | FCCTX vs Lyncha OR (95% CI) | FCCTX vs non-AC1a OR (95% CI) | Lynch vs non-AC1a OR (95% CI) |
|---|---|---|---|---|---|---|
|
Cancer subsite | ||||||
| Caecum | 17 (12%) | 55 (22%) | 1034 (13%) | 0.18 (0.09, 0.37) | 0.95 (0.54, 1.67) | 5.2 (3.32, 8.14) |
| Ascending | 15 (10%) | 64 (26%) | 1129 (14%) | 0.13 (0.06, 0.27) | 0.66 (0.35, 1.22) | 5.22 (3.37, 8.07) |
| Transverse | 13 (9%) | 31 (13%) | 578 (7%) | 0.27 (0.12, 0.59) | 1.18 (0.63, 2.21) | 4.44 (2.67, 7.41) |
| Descending | 7 (5%) | 14 (6%) | 438 (6%) | 0.38 (0.14, 1.08) | 0.78 (0.35, 1.74) | 2.03 (1.03, 3.99) |
| Sigmoid | 37 (25%) | 22 (9%) | 1931 (25%) | 1.02 (0.51, 2.04) | 0.98 (0.63, 1.52) | 0.96 (0.55, 1.66) |
| Rectum | 50 (34%) | 37 (15%) | 2455 (31%) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Missing/other |
7 (5%) |
22 (9%) |
313 (4%) |
|
|
|
|
T-stage | ||||||
| T1 | 22 (15%) | 27 (11%) | 958 (12%) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| T2 | 26 (18%) | 48 (20%) | 1328 (17%) | 0.75 (0.35, 1.57) | 0.78 (0.43, 1.40) | 1.04 (0.64, 1.70) |
| T3 | 74 (51%) | 127 (52%) | 4242 (54%) | 0.85 (0.45, 1.63) | 0.65 (0.39, 1.07) | 0.76 (0.49, 1.18) |
| T4 | 11 (8%) | 9 (4%) | 576 (7%) | 1.75 (0.60, 5.05) | 0.72 (0.34, 1.52) | 0.41 (0.19, 0.89) |
| Missing |
13 (8%) |
34 (13%) |
774 (10%) |
|
|
|
|
Differentiation | ||||||
| Well | 22 (15%) | 21 (9%) | 633 (8%) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Moderate | 97 (66%) | 127 (52%) | 4712 (60%) | 0.88 (0.45, 1.75) | 0.62 (0.38, 1.02) | 0.70 (0.43, 1.15) |
| Poor | 16 (11%) | 55 (22%) | 1149 (15%) | 0.33 (0.14, 0.78) | 0.41 (0.21, 0.82) | 1.25 (0.73, 2.14) |
| Missing/other |
11 (8%) |
42 (17%) |
1384 (18%) |
|
|
|
|
Histology | ||||||
| Adenocarcinoma | 132 (90%) | 191 (78%) | 6771 (86%) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Mucinous | 11 (8%) | 41 (17%) | 856 (11%) | 0.39 (0.19, 0.80) | 0.68 (0.36, 1.27) | 1.72 (1.21, 2.45) |
| Signet ring | 1 (1%) | 4 (2%) | 79 (1%) | 0.38 (0.04, 3.44) | 0.68 (0.09, 4.96) | 1.79 (0.64, 5.07) |
| Missing/other |
2 (1%) |
9 (4%) |
172 (2%) |
|
|
|
|
Additional features (yes/no) (% yes)b | ||||||
| Peritumoural lymphocytes | 23/57 (28%) | 61/71 (46%) | 954/1608 (37%) | 0.49 (0.26, 0.90) | 0.75 (0.45, 1.25) | 1.54 (1.07, 2.23) |
| Crohn's-like lymphocytes | 14/60 (19%) | 61/70 (37%) | 627/1843 (25%) | 0.27 (0.14, 0.54) | 0.78 (0.43, 1.41) | 2.84 (1.97, 4.10) |
| Tumour-infiltrating lymphocytes | 20/65 (24%) | 98/43 (70%) | 704/1920 (27%) | 0.14 (0.07, 0.26) | 0.89 (0.53, 1.50) | 6.41 (4.40, 9.36) |
| Venous invasion | 16/79 (11%) | 9/135 (4%) | 735/4027 (9%) | 3.21 (1.35, 7.65) | 1.27 (0.73, 2.21) | 0.40 (0.20, 0.79) |
Abbreviations: AC1=Amsterdam Criteria-1; FCCTX=Familial Colorectal Cancer Type X.
a
All models are adjusted for age at diagnosis, sex, and study site. Reference group is those without the characteristic.
b
These features were only collected at four of six study sites (Mayo Clinic, Australasia, UH, and CCO).